This podcast is based on the recent investor presentation by Fusion Antibodies PLC and covers the company's performance in the first half of fiscal year 2025. Key highlights include a 123% increase in revenue, driven by a revamped commercial strategy focusing on early client engagement and proprietary antibody discovery platforms (Optimal, Optiphage, and AIAB). Financials show revenue exceeding the total for fiscal year 2024, though profitability remains elusive. The podcast also details Fusion's antibody services, including discovery, engineering, and supply, emphasizing their world-leading expertise and commitment to accelerating antibody development for various clients, from large pharmaceutical companies to startups.